Latest News
& Press Releases

The whistleblower claim was brought by former employee Michael Bawduniak, who accused the company of paying off doctors to favor its multiple sclerosis drugs over those of its competitors.

Sandoz hopes its high-concentration formulation of an already greenlit biosimilar will be approved by the time AbbVie’s blockbuster drug Humira loses patent protection in the United States.

According to a study, people with certain gut disorders may be at greater risk of Alzheimer’s disease, and researchers have discovered a potential use for ASOs against cystic fibrosis.

As Severin Schwan prepares to step aside from the day-to-day leadership of Roche, Thomas Schinecker is waiting in the wings to assume the company’s top leadership spot.

A new study published in Frontiers in Aging Neuroscience by researchers at Tufts University further supports the theory that there’s a link between gum disease and Alzheimer’s.

Vertex and Verve announced they had entered an exclusive four-year research partnership to discover and nurture a gene editing therapy for yet-undisclosed liver disease.

With a deep knowledge of the urology space, Urovant is developing a unique approach to treating overactive bladder - an injectable plasmid human cDNA encoding maxi-K channel gene therapy.

Hansa Biopharma secured $70 million in non-dilutive financing, OSE secured $300 million in funding while CN Bio opened a new contract research facility and more global biopharma news.

As monkeypox continues to spread across the globe, health experts suggest monitoring vaccine effectiveness, population spread and at-risk groups.

The new chief executive officer of Versanis is going to push the obesity drug bimagrumab in the limelight against Novo and Lilly’s drug. Here’s all that you need to know.

Total sales for the quarter were $12.8 billion, with its innovative medicines, which include key assets, bringing in $10.8 billion.

Auron Therapeutics reels in $48 million to identify novel AI-based cancer targets, Frontera scoops up $160 million for AAV gene therapy and tech manufacturing and MMI scores $75 million for robotic microsurgery.

Expanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories.

• $5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to provide Company with cash runway into 2027 • $4.5 million of accrued VAT refunds and R&D refundable tax credits from UK subsidiary begin maturing, including $1.9 million VAT cash refund expected in June 2026 • Successful EMA and Australia TGA (ATGA) meetings aligned around use of existing biomarker and pending release of 3-year overall survival data to support Conditional Marketing Authorisations (CMAs) for OST-HER2 in prevention or delay of recurrence in fully-resected, pulmonary metastatic osteosarcoma (“Metastatic Osteosarcoma”) • 2.5-year overall survival data expected to be released during ASCO 2026 • EMA and ATGA have aligned on key design aspects of confirmatory Phase 3 Metastatic Osteosarcoma protocol required to have commenced prior to grant of CMAs or FDA BLA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint • Upcoming U.S. FDA Type C meeting and U.K. MHRA SAM meeting to align with EMA & ATGA prior to Australia Clinical Trial Notification submission for Phase 3, including alignment on 3-year overall survival as a primary clinical efficacy endpoint. U.S. FDA (“FDA”) Pre-BLA meeting to confirm alignment on surrogate and primary clinical efficacy endpoints with EMA/ATGA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint, and seek decisions on rolling review acceptance and RMAT designation following the EMA and U.K. MHRA granting ATMP designation (EMA/MHRA RMAT equivalent) for OST-HER2 in Metastatic Osteosarcoma • OS Animal Health S-1 filing for proposed ‘Go-Public’ transaction and receipt of SEC comments